fundament help sentiment
settlement remov biosimilar competit overhang
last night file indic potenti settlement ipr regard potenti
soliri biosimilar welcom develop alexion sharehold despit limit
near-term impact fundament competit threat creat major overhang
share lead recent downgrad settlement could improv
sentiment margin clarifi futur prospect franchis
assign meaning share model soliri biosimilar share
biosimilars/competitor combin pnh/ahu assumpt standard
care shift ultomiri time biosimilar hit market
later realiz hot debat topic among investor greater clariti
benefit sentiment notabl ultim impact potenti competitor pnh
mg proven launch product reveal new dynam
complement competit landscap given progress biosimilar threat
threat innov compound rais po
howev chang revenu earn forecast maintain neutral rate
detail case
file ptab patent trial appeal board request delay oral
argument origin schedul date june provid time side
final settlement termin ipr proceed board grant new
date june patent question relat method treat pnh use
soliri set expir given ultomiri alreadi standard
care pnh expect minim soliri market share come year settlement
allow soliri biosimilar time frame would signific effect
alexion franchis view forecast ultomiri revenu
pnh/ahu combin compar soliri
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate alexion neutral expect neg
sentiment competit threat base
franchis outweigh commerci clinic
execut strong growth near term mg
nmo soliri launch eventu switch
ultomiri impact come
competitor becom certain
price object alexion base npv analysi
forecast sale approv product soliri ultomiri strensiq
kanuma well probabl adjust assum
wacc line peer compani similar size risk differ
termin valu asset depend specif characterist patent
protect given assumpt estim valu soliri
ultomiri strensiq kanuma net
cash round po
upsid risk competitor trial could fail increas investor confid alexion
downsid risk posit competitor data expedit fda approv could exacerb
fear share loss
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
